Pharmaceutical Overdose Deaths, United States, 2010

Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, Georgia, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 02/2013; 309(7):657-9. DOI: 10.1001/jama.2013.272
Source: PubMed
Download full-text


Available from: Karin A Mack, Oct 13, 2014
  • Source
    • "This increase has been accompanied by a dramatic rise in prescription opioid-associated morbidity and mortality[2]. In 2010, more than 16,000 deaths were attributed to prescription opioids[3], making them a leading cause of injury death in the general population[4]. Among women, opioid overdose deaths have risen five-fold from 1999–2010[5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Opioid-based analgesic therapy represents a cornerstone of pain management after surgery. The recent rise in opioid sales and opioid overdoses suggests it is important to maximize the safety of opioid prescribing after surgery. Given that patients may live with other family members in the home, safe storage and appropriate disposal of excess opioids after hospital discharge are necessary to prevent unintended secondary exposures. Identifying characteristics of patients who are likely to be prescribed excess opioids after surgery may enable more targeted prescription practices and safety interventions. Our study aimed to elucidate patient-reported opioid use patterns and modes of home storage of opioids among patients discharged home after Cesarean section (C-section) and thoracic surgery. Specifically, we sought to identify characteristics of patients who reported using about half or more versus less of the opioids prescribed to them for use after hospital discharge.
    Full-text · Article · Jan 2016 · PLoS ONE
  • Source
    • "Opioid misuse and dependence are reaching epidemic proportions in the United States (US), resulting in overdoses, premature death, infectious disease and economic costs of $56 billion annually (Becker, Sullivan, Tetrault, Desai, & Fiellin, 2008; Birnbaum et al., 2011; Clausen, Waal, Thoresen, & Gossop, 2009; Hser, Hoffman, Grella, & Anglin, 2001; Jones, Mack, & Paulozzi, 2013; Paulozzi, 2012; SAMHSA, 2010; Shah, Lathrop, Reichard, & Landen, 2008; Wisniewski, Purdy, & Blondell, 2008). The problem is increasingly urgent in rural areas which often struggle with high rates of opioid misuse and a lack of available treatment options (Fortney & Booth, 2001; Lenardson & Gale, 2007; Rosenblum et al., 2011; Rounsaville & Kosten, 2000; Sigmon, 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the effectiveness of agonist maintenance for opioid dependence, individuals can remain on waitlists for months, during which they are at significant risk for morbidity and mortality. Interim dosing, consisting of daily medication without counseling, can reduce these risks. In this pilot study, we examined the initial feasibility of a novel technology-assisted interim buprenorphine treatment for waitlisted opioid-dependent adults. Following buprenorphine induction during Week 1, participants (n=10) visited the clinic at Weeks 2, 4, 6, 8, 10 and 12 to ingest their medication under staff observation, provide a urine specimen and receive their remaining doses via a computerized Med-O-Wheel Secure device. They also received daily monitoring via an Interactive Voice Response (IVR) platform, as well as random call-backs for urinalysis and medication adherence checks. The primary outcome was percent of participants negative for illicit opioids at each 2-week visit, with secondary outcomes of past-month drug use, adherence and acceptability. Participants achieved high levels of illicit opioid abstinence, with 90% abstinent at the Week 2 and 4 visits and 60% at Week 12. Significant reductions were observed in self-reported past-month illicit opioid use (p<.001), opioid withdrawal (p<.001), opioid craving (p<.001) and ASI Drug composite score (p=.008). Finally, adherence with buprenorphine administration (99%), daily IVR calls (97%) and random call-backs (82%) was high. Interim buprenorphine treatment shows promise for reducing patient and societal risks during delays to conventional treatment. A larger-scale, randomized clinical trial is underway to more rigorously examine the efficacy of this treatment approach. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Full-text · Article · Jul 2015 · Addictive behaviors
  • Source
    • "780 General symptoms that is, alteration of consciousness, and so forth [1] 521, 522, 523, 525.3, 525.9, 873.63 Nontraumatic dental conditions 786 Respiratory syndrome [1] 729 Soft tissue disorderdfasciitis or limb pain [1] 722 Vertebrae disorders [1] Chronic pain 719 Joint disorder [1] 307.81, 339.00, 339.01, 339.02, 339.03, 339.04, 339.05, 339.09, 339.10, 339.11, 339.12, 339.20, 339.21, 339.22, 339.3, 339.41, 339.42, 339.43, 339.44, 339.81, 339.82, 339.83, 339.84, 339.85, 339.89, 346.0, 346.00, 346.01, 346.02, 346.03, 346.1, 346.10, 346.11, 346.12, 346.13, 346.2, 346.20, 346.21, 346.22, "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prescription drug overdose (PDO) deaths are a critical public health problem in the United States. This study aims to assess the association between emergency department (ED) utilization patterns in a cohort of ED patients and the risk of subsequent unintentional PDO mortality. Using data from the New York Statewide Planning and Research Cooperative System for 2006-2010, a nested case-control design was used to examine the relationship between ED utilization patterns in New York State residents of age 18-64 years and subsequent PDO death. The study sample consisted of 2732 case patients who died of PDO and 2732 control ED patients who were selected through incidence density sampling. With adjustment for demographic characteristics, and diagnoses of pain, substance abuse, and psychiatric disorders, the estimated odds ratios of PDO death relative to one ED visit or less in the previous year were 4.90 (95% confidence interval [CI]: 4.50-5.34) for those with two ED visits, 16.61 (95% CI: 14.72-18.75) for those with three ED visits, and 48.24 (95% CI: 43.23-53.83) for those with four ED visits or more. Frequency of ED visits is strongly associated with the risk of subsequent PDO death. Intervention programs targeting frequent ED users are warranted to reduce PDO mortality. Copyright © 2015 Elsevier Inc. All rights reserved.
    Full-text · Article · Apr 2015 · Annals of epidemiology
Show more